Ligand's president, CEO resigns

By Elaine Rigoli

Tampa, Fla., Aug. 1 - David E. Robinson has resigned as Ligand Pharmaceuticals, Inc.'s chairman, president, chief executive officer and director of the company.

Ligand said it will immediately begin a search for a new chief executive officer and has named Henry F. Blissenbach interim chief executive officer and chairman, effective immediately.

In a related action, the company's board of directors appointed current director John W. Kozarich to the audit committee of the company's board of directors to replace Blissenbach. In addition, Alexander D. Cross has replaced Blissenbach on the compensation committee and the nominating committee, and John Groom has been named chairman of the compensation committee.

Ligand's second-quarter earnings will be released Aug. 9.

Ligand is a specialty pharmaceutical company located in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.